Status:

COMPLETED

Liraglutide and Peripheral Artery Disease

Lead Sponsor:

University of Campania Luigi Vanvitelli

Conditions:

Type 2 Diabetes

Peripheral Arterial Disease

Eligibility:

All Genders

35+ years

Phase:

PHASE4

Brief Summary

STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic ri...

Detailed Description

An 18-month extension of the follow-up will be performed for all the study population, according to guidelines and good clinical practice. The follow-up will include the glyco-metabolic parameters and...

Eligibility Criteria

Inclusion

  • diagnosis of type 2 diabetes within at least 6 months
  • peripheral arterial disease documented within al least 1 year by doppler ultrasound, angio-CT or arteriography
  • peripheral transcutaneous oxygen pressure between 30 and 49 mmHg on anterior and/or posterior tibial arteries
  • Hba1c 6,5-8%
  • treatment of diabetes with metformin, insulin and/or sulfonylurea

Exclusion

  • diagnosis of type 1 diabetes
  • current treatment with GLP-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase -4 (DPP-4) inhibitors
  • GLP-1RAs allergy or intolerance
  • participation to other clinical studies
  • history of pancreatitis, thyroid disease, diabetic gastroparesis or inflammatory bowel disease
  • current or planned pregnancy
  • acute myocardial infarction and/or acute cerebrovascular disease within 14 days from the screening visit
  • planned revascularization procedure
  • renal function with estimated glomerular filtration rate (eGFR) below 15 ml/min
  • history of cancer and/or oncological treatment within 5 years from the screening visit
  • current treatment with corticosteroids
  • psychiatric or other clinical conditions which may interfere with the study

Key Trial Info

Start Date :

February 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2022

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT04881110

Start Date

February 1 2021

End Date

December 31 2022

Last Update

March 3 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli

Napoli, Italy, 80138